Comprehensive Treatment with Chinese Medicine in Patients with Advanced Non-Small Cell Lung Cancer: A Multicenter, Prospective, Cohort Study

作     者：LIU Jie LIN Hong-sheng HOU Wei HUA Bao-jin ZHANG Pei-tong LI Jie WANG Shen-yu XIE Ying ZHANG Yue XIE Guang-ru ZHANG Mei-ying SHI Wen-guang GUAN Nian-bo GUAN Tian-yu LI Cong-huang LU Li-yuan ZHANG Ying LI Dao-rui LIU Hao 

作者机构：Department of Oncology Guang'anmen Hospital China Academy of Chinese Medical Sciences Department of Integrative Oncology Liaoning Cancer Hospital Department of Traditional Chinese Medicine Shanxi Cancer Hospital Traditional Chinese Medicine Department Jilin Cancer Hospital Department of Integrative Oncology Tianjin Medical University Cancer Institute and Hospital 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2017年第23卷第10期

页      面：733-739页

核心收录：

学科分类：1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学] 

基　　金：Supported by National Key Technologies Research and Development Program for the 11th Five-Year Plan(No.2006BAI04A05) 

主　　题：advanced non small cell lung cancer Chinese medicine integrative medicine 

摘      要：Objective： To determine whether additional Chinese medicine（CM） could prolong survival and improve the quality of life（QOL） in patients with advanced non-small cell lung cancer（NSCLC） compared with Western medicine（WM） alone. Methods： This was a multicenter, prospective cohort study. A total of 474 hospitalized patients with stage Ⅲ–Ⅳ NSCLC were recruited and divided into 2 groups. Patients in the WM group received radiotherapy, chemotherapy, and optimal supportive therapy according to the National Comprehensive Cancer Network（NCCN） guidelines. In the integrative medicine（IM） group, individualized CM（Chinese patent medicines and injections） and WM were administered. The primary end point was overall survival, and the secondary end points were time to disease progression, adverse events, and QOL. Follow-up clinical examinations and chest radiography were performed every 2 months. Results： The median survival was 16.60 months in the IM group and 13.13 months in the WM group（P〈0.01）. The incidences of loss of appetite, nausea, and vomiting in the IM group were significantly lower than those in the WM group（P〈0.05）. The QOL based on Functional Assessment of Cancer Therapy-Lung in the IM group was markedly higher than that in the WM group at the fourth course（P〈0.05）. Conclusions： Additional CM may prolong survival and improve the QOL patients with NSCLC. The adverse effects of radio-and chemotherapy may be attenuated as CM is used in combination with conventional treatments.